Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Bldg. H821, 65926 Frankfurt am Main, Germany.
Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Bldg. H821, 65926 Frankfurt am Main, Germany.
Cell Metab. 2018 Aug 7;28(2):217-227.e13. doi: 10.1016/j.cmet.2018.05.028. Epub 2018 Jun 21.
Fatty acid esters of hydroxylated fatty acids (FAHFAs) were discovered as a novel class of endogenous mammalian lipids whose profound effects on metabolism have been shown. In the current study, in vitro and in vivo the metabolic effects of two of these FAHFAs, namely palmitic acid-5- (or -9) -hydroxy-stearic acid (5- or 9-PAHSA, respectively) were profiled. In DIO mice fed with differentially composed low- or high-fat diets, acute and subchronic treatment with 5-PAHSA and 9-PAHSA alone, or in combination, did not significantly improve the deranged metabolic status. Neither racemic 5- or 9-PAHSA, nor the enantiomers were able to: (1) increase basal or insulin-stimulated glucose uptake in vitro, (2) stimulate GLP-1 release from GLUTag cells, or (3) induce GSIS in rat, mouse, or human islets or in a human pancreatic β cell line. Therefore, our data do not support the further development of PAHSAs or their derivatives for the control of insulin resistance and hyperglycemia.
羟基化脂肪酸的脂肪酸酯(FAHFAs)被发现是一类新型的内源性哺乳动物脂质,其对代谢的深远影响已得到证实。在本研究中,我们分别在体外和体内研究了这两种 FAHFAs 中的两种,即棕榈酸-5-(或-9)-羟基硬脂酸(5-PAHSA 或 9-PAHSA)的代谢效应。在喂食不同组成的低脂或高脂饮食的 DIO 小鼠中,单独或联合使用 5-PAHSA 和 9-PAHSA 进行急性和亚慢性治疗,并没有显著改善紊乱的代谢状态。外消旋 5-PAHSA 或 9-PAHSA 及其对映体均不能:(1)增加体外基础或胰岛素刺激的葡萄糖摄取;(2)刺激 GLUTag 细胞释放 GLP-1;(3)在大鼠、小鼠、人胰岛或人胰腺β细胞系中诱导 GSIS。因此,我们的数据不支持进一步开发 PAHSAs 或其衍生物来控制胰岛素抵抗和高血糖。